Verastem (VSTM) Shares Outstanding (Diluted Average) (2016 - 2025)
Verastem (VSTM) recorded quarterly Shares Outstanding (Diluted Average) of $69.3 million in Q4 2025, up 7.35% quarter-over-quarter from $64.6 million in Q3 2025, and up 94.07% on a YoY basis from $35.7 million in Q4 2024.
Verastem (VSTM) Shares Outstanding (Diluted Average) (2016 - 2025) Analysis & Trends
Verastem's Shares Outstanding (Diluted Average) history runs 10 years deep, the most recent figure standing at $69.3 million for Q4 2025.
- In Q4 2025, Shares Outstanding (Diluted Average) rose 94.07% year-over-year to $69.3 million; the TTM figure through Dec 2025 stood at $69.3 million (up 94.07% YoY), while the FY2025 annual figure was $69.3 million, up 94.07% from the prior year.
- Shares Outstanding (Diluted Average) was $69.3 million for Q4 2025 at Verastem, up from $64.6 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $200.7 million in Q1 2023 to a low of $14.5 million in Q4 2021.
- Historically, Shares Outstanding (Diluted Average) has averaged $96.6 million across 5 years, with a median of $64.6 million in 2025.
- The sharpest annual moves came in 2021 and 2023: Shares Outstanding (Diluted Average) soared 9379.55% in 2021, then plunged 89.24% in 2023.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $14.5 million in 2021, then advanced by 11.03% to $16.1 million in 2022, then surged by 36.66% to $22.1 million in 2023, then surged by 61.93% to $35.7 million in 2024, then soared by 94.07% to $69.3 million in 2025.
- The last three Shares Outstanding (Diluted Average) figures came in at $69.3 million (Q4 2025), $64.6 million (Q3 2025), and $54.2 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Verastem | 407.42 Mn | 225.74 Mn | 15.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 69.31 Mn |
| Sep 30, 2025 | 64.56 Mn |
| Mar 31, 2025 | 54.17 Mn |
| Dec 31, 2024 | 35.71 Mn |
| Sep 30, 2024 | 31.35 Mn |
| Mar 31, 2024 | 26.83 Mn |
| Dec 31, 2023 | 22.05 Mn |
| Sep 30, 2023 | 20.45 Mn |
| Mar 31, 2023 | 200.68 Mn |
| Dec 31, 2022 | 16.14 Mn |
| Sep 30, 2022 | 190.00 Mn |
| Jun 30, 2022 | 186.36 Mn |
| Mar 31, 2022 | 186.26 Mn |
| Dec 31, 2021 | 14.54 Mn |
| Sep 30, 2021 | 179.86 Mn |
| Jun 30, 2021 | 171.99 Mn |
| Mar 31, 2021 | 171.59 Mn |
| Dec 31, 2020 | 153,330.00 |
| Sep 30, 2020 | 147.77 Mn |
| Dec 31, 2019 | 74.58 Mn |